| Redox/pH dual stimuli-responsive biodegradable nanohydrogels with varying responses to dithiothreitol and glutathione for controlled drug release YJ Pan, YY Chen, DR Wang, C Wei, J Guo, DR Lu, CC Chu, CC Wang Biomaterials 33 (27), 6570-6579, 2012 | 392 | 2012 |
| IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype D Alizadeh, RA Wong, X Yang, D Wang, JR Pecoraro, CF Kuo, B Aguilar, ... Cancer Immunology Research 7 (5), 759-772, 2019 | 372 | 2019 |
| Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response DR Wang, XL Wu, YL Sun Signal Transduction and Targeted Therapy 7 (1), 1-27, 2022 | 291 | 2022 |
| Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL J Zhang, Y Hu, J Yang, W Li, M Zhang, Q Wang, L Zhang, G Wei, Y Tian, ... Nature 609 (7926), 369-374, 2022 | 220 | 2022 |
| Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity D Wang, B Aguilar, R Starr, D Alizadeh, A Brito, A Sarkissian, JR Ostberg, ... JCI insight 3 (10), 2018 | 220 | 2018 |
| CAR T cells for brain tumors: Lessons learned and road ahead D Akhavan, D Alizadeh, D Wang, MR Weist, JK Shepphird, CE Brown Immunological reviews 290 (1), 60-84, 2019 | 213 | 2019 |
| Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma D Wang, R Starr, WC Chang, B Aguilar, D Alizadeh, SL Wright, X Yang, ... Science translational medicine 12 (533), eaaw2672, 2020 | 204 | 2020 |
| CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies D Wang, BC Prager, RC Gimple, B Aguilar, D Alizadeh, H Tang, D Lv, ... Cancer Discovery 11 (5), 1192-1211, 2021 | 126 | 2021 |
| Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study Y Hu, Y Zhou, M Zhang, H Zhao, G Wei, W Ge, Q Cui, Q Mu, G Chen, ... Cell research 32 (11), 995-1007, 2022 | 118 | 2022 |
| IFNγ is critical for CAR T cell–mediated myeloid activation and induction of endogenous immunity D Alizadeh, RA Wong, S Gholamin, M Maker, M Aftabizadeh, X Yang, ... Cancer discovery 11 (9), 2248-2265, 2021 | 118 | 2021 |
| GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial M Zhang, G Wei, L Zhou, J Zhou, S Chen, W Zhang, D Wang, X Luo, J Cui, ... The Lancet Haematology 10 (2), e107-e116, 2023 | 109 | 2023 |
| Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial CE Brown, JC Hibbard, D Alizadeh, MS Blanchard, HM Natri, D Wang, ... Nature Medicine, 1-12, 2024 | 89 | 2024 |
| Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data P Sahoo, X Yang, D Abler, D Maestrini, V Adhikarla, D Frankhouser, ... Journal of the Royal Society Interface 17 (162), 20190734, 2020 | 83 | 2020 |
| Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer L Xiao, X Lan, X Shi, K Zhao, D Wang, X Wang, F Li, H Huang, J Liu Cell death & disease 8 (5), e2803, 2017 | 80 | 2017 |
| VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells Y Chen, D Meng, H Wang, R Sun, D Wang, S Wang, J Fan, Y Zhao, ... Neuro-oncology 17 (3), 407-418, 2014 | 64 | 2014 |
| Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models X Si, L Xiao, CE Brown, D Wang International Journal of Molecular Sciences 23 (6), 3154, 2022 | 41 | 2022 |
| Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid J Portnow, D Wang, MS Blanchard, V Tran, D Alizadeh, R Starr, R Dodia, ... JAMA oncology 6 (12), 1947-1951, 2020 | 41 | 2020 |
| Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis Y Hu, M Zhang, T Yang, Z Mo, G Wei, R Jing, H Zhao, R Chen, C Zu, T Gu, ... New England Journal of Medicine 390 (16), 1467-1480, 2024 | 32 | 2024 |
| Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in … Y Hu, C Zu, M Zhang, G Wei, W Li, S Fu, R Hong, L Zhou, W Wu, J Cui, ... EClinicalMedicine 60, 2023 | 29 | 2023 |
| In vitro tumor cell rechallenge for predictive evaluation of chimeric antigen receptor T cell antitumor function D Wang, R Starr, D Alizadeh, X Yang, SJ Forman, CE Brown JoVE (Journal of Visualized Experiments), e59275, 2019 | 27 | 2019 |
